| 3.15 -0.08 (-2.48%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.95 | 1-year : | 4.62 |
| Resists | First : | 3.39 | Second : | 3.95 |
| Pivot price | 2.98  |
|||
| Supports | First : | 2.74 | Second : | 2.33 |
| MAs | MA(5) : | 3.21 |
MA(20) : | 2.85 |
| MA(100) : | 3.13 |
MA(250) : | 3.56 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 82.4 |
D(3) : | 85.4 |
| RSI | RSI(14): 59.5 |
|||
| 52-week | High : | 4.8 | Low : | 2.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EVO ] has closed below upper band by 35.2%. Bollinger Bands are 62.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.19 - 3.21 | 3.21 - 3.23 |
| Low: | 3.01 - 3.03 | 3.03 - 3.05 |
| Close: | 3.12 - 3.15 | 3.15 - 3.18 |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Fri, 24 Apr 2026
Evotec (NASDAQ:EVO) Sees Strong Trading Volume - Should You Buy? - MarketBeat
Fri, 24 Apr 2026
Evotec (EVO) appoints Claire Hinshelwood CFO as Paul Hitchin exits - Stock Titan
Fri, 24 Apr 2026
Evotec Announces Chief Financial Officer Transition - Eagle-Tribune
Fri, 24 Apr 2026
Evotec Announces Chief Financial Officer Transition - News-Press NOW
Thu, 23 Apr 2026
Evotec (NASDAQ:EVO) Shares Gap Down - Should You Sell? - MarketBeat
Thu, 23 Apr 2026
H.C. Wainwright Initiates Coverage of Evotec (EVO) with a Buy Rating - Insider Monkey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 355 (M) |
| Shares Float | 133 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 2.6 (%) |
| Shares Short | 349 (K) |
| Shares Short P.Month | 352 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.7 |
| Profit Margin | -13.2 % |
| Operating Margin | 13.2 % |
| Return on Assets (ttm) | -2 % |
| Return on Equity (ttm) | -11.8 % |
| Qtrly Rev. Growth | 14.5 % |
| Gross Profit (p.s.) | 0.32 |
| Sales Per Share | 2.21 |
| EBITDA (p.s.) | 0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -9.27 |
| PEG Ratio | 1.4 |
| Price to Book value | 1.16 |
| Price to Sales | 1.41 |
| Price to Cash Flow | -121.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|